bpc-157 human clinical trials 2025 trial recruiting studies kpv bpc 157 tb500 dihexa human status BPC-157 has already hit the

Each 3ml vial contains approximately 1.66mg/ml of BPC-157 and 3.33mg/ml of TB-500

Reported effects in human use are generally mild injection-site reactions, lightheadedness, fatigue, nausea

Hypoglycemia (the primary acute risk) In the Increlex program, hypoglycemia was reported in 30 of 71 subjects (42%)

SIRT1 activates PGC-1alpha (mitochondrial biogenesis) and deacetylates p53 (DNA repair)

2010 Sep;95(9):4291-304

The peptide has been studied primarily for its tissue-healing properties: accelerating wound healing, supporting gut lining repair, reducing inflammation, and potentially protecting various organs from damage